This product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. This product also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

1. It can inhibit the secretion of growth hormone, thyroid stimulating hormone, insulin, and glucagon; 2. It can inhibit the secretion of gastric acid stimulated by the test meal and pentagastrin, and inhibit the release of pepsin and gastrin; 3. It can significantly reduce visceral blood flow, reduce portal vein pressure, reduce collateral circulation blood flow and pressure, and reduce liver blood flow; 4. It can reduce the endocrine secretion of the pancreas, the secretion of the stomach, small intestine, and gallbladder, reduce enzyme activity, and have a protective effect on pancreatic cells; 5. It can inhibit the secretion of glucagon; 6. It can affect gastrointestinal absorption and nutritional function.

Intraperitoneal injection of the drug into mice with cholestatic jaundice induced by 1-naphthyl isothiocyanate can reduce serum aspartate aminotransferase, alanine aminotransferase and serum conjugated bilirubin levels, and alleviate liver cell damage in the model animals.